Browsing by Author Maze, Dawn

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 3 of 3
TitleAuthor(s)Issue Date
 
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms
Journal:Leukemia
Murphy, TracyMason, Jacqueline M.Leber, BrianBray, Mark R.Chan, Steven M.Gupta, VikasKhalaf, DinaMaze, DawnMcNamara, Caroline J.Schimmer, Aaron D.Schuh, Andre C.Sibai, HassanTrus, MichaelValiquette, DebbieMartin, KylieNguyen, LinhLi, XuanMak, Tak W.Minden, Mark D.Yee, Karen W.L.
1-Mar-2024
 
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study
Journal:The Lancet Haematology
Mesa, RubenGill, HarinderZhang, LeiJin, JieKirito, KeitaKomatsu, NorioQin, AlbertXiao, ZhijianTashi, TsewangShimoda, KazuyaOhishi, KohshiChen, SuningZuo, XuelanShirane, ShuichiHu, YuZhang, SujiangWang, YiTakenaka, KatsutoIchii, MichikoXu, NaShih, Lee-YungLim, Ken-HongLee, Sung-EunBae, Sung HwaTeo, Winnie Z YMaze, DawnOh, Stephen TBose, PrithvirajSato, ToshiakiZagrijtschuk, OlehLin, SheenaShih, Weichung JoeMascarenhas, JohnMasarova, Lucia
1-Nov-2025
 
Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial
Journal:Journal of Clinical Oncology
Mesa, Ruben AGill, HarinderXiao, ZhijianKomatsu, NorioQin, AlbertTashi, TsewangZhang, LeiJin, JieKirito, KeitaOhishi, KohshiShirane, ShuichiShih, Lee-YungLee, Sung-EunTeo, Winnie ZYMaze, DawnOh, StephenSato, ToshiakiShih, WeichungMascarenhas, JohnMasarova, LuciaSURPASS-ET Study Group
1-Jun-2025
Showing results 1 to 3 of 3